Open AccessPatiromer Acetate Induced Hypercalcemia: An Unreported Adverse Effect
Author(s) -
Shreeyukta Bhattarai,
Stephen Pupillo,
Gulshan Man Singh Dangol,
Erdal Sarac
Publication year - 2019
Publication title -
case reports in nephrology
Language(s) - English
Resource type - Journals
eISSN - 2090-6641
pISSN - 2090-665X
DOI - 10.1155/2019/3507407
Subject(s) - hyperkalemia , medicine , kidney disease , constipation , adverse effect , vomiting , intensive care medicine , diarrhea
Hyperkalemia, a potential life threating condition, is a commonly encountered problem in chronic kidney disease (CKD) patients. Patiromer acetate, a nonabsorbable cation exchange polymer, is a gastrointestinal agent for chronic therapy in patients with persistent hyperkalemia. Patiromer is generally well tolerated in patients; common side effects are gastrointestinal, such as diarrhea, constipation, flatulence, and vomiting. Hypercalcemia, although a theoretical possibility, has not been reported in any major clinical trials. We present a case of hypercalcemia associated with patiromer acetate used for treatment of hyperkalemia in a stage IV CKD patient. Clinicians should be aware of the possibility of hypercalcemia while taking patiromer.